BiomX (NYSEMKT:PHGE) Shares Down 5.4%

BiomX Inc. (NYSEMKT:PHGE) shares traded down 5.4% on Monday . The stock traded as low as $1.10 and last traded at $1.13. 78,243 shares traded hands during mid-day trading, an increase of 14% from the average session volume of 68,601 shares. The stock had previously closed at $1.19.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of BiomX in a research note on Friday, August 16th. Laidlaw initiated coverage on BiomX in a report on Tuesday, May 28th. They set a “buy” rating and a $25.00 price objective on the stock.

BiomX Trading Down 5.4 %

The firm has a market cap of $78.60 million, a price-to-earnings ratio of -1.85 and a beta of 1.30. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.84 and a quick ratio of 2.84. The business has a 50-day moving average of $2.12 and a 200-day moving average of $3.02.

Institutional Trading of BiomX

An institutional investor recently bought a new position in BiomX stock. Ikarian Capital LLC bought a new stake in BiomX Inc. (NYSEMKT:PHGE) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 10,817,327 shares of the company’s stock, valued at approximately $4,868,000. Ikarian Capital LLC owned about 19.59% of BiomX at the end of the most recent quarter. Institutional investors own 40.57% of the company’s stock.

About BiomX

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.